Company Mabvax Therapeutics Holdings Inc Nasdaq

Equities

US55414P7024

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.

Managers	Title	Age	Since
John David Hansen CEO	Chief Executive Officer	72	-
Philip O. Livingston CTO	Chief Tech/Sci/R&D Officer	81	14-07-07
Paul W. Maffuid CTO	Chief Tech/Sci/R&D Officer	68	14-07-07
Wolfgang W. Scholz PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Philip O. Livingston CTO	Chief Tech/Sci/R&D Officer	81	14-07-07

	Vote	Quantity	Free-Float	Total Float
Stock A	0	33,333	0	92.02 %
Stock B	0	44,104	0
Stock C	1	9,429,582	8,677,104 ( 92.02 %)

MabVax Therapeutics Holdings, Inc.

559 Evans Mountain Road

72031, Clinton

+858-259-9405

address Mabvax Therapeutics Holdings Inc

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.46%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs